Previous studies have shown that optimizing the information bottleneck can significantly improve the robustness of deep neural networks.

Inflammatory bowel disease (IBD) impacts 1.6 million people in the U.S. -- and a new artificial intelligence-generated drug could help alleviate symptoms. Insilico Medicine, an AI-driven biotech company based in Hong Kong and in New York City, recently announced that its new AI-designed IBD drug -- ISM5411 -- has entered Phase I clinical trials. This is Insilico's fifth AI-designed drug to enter the pipeline. WHAT IS ARTIFICIAL INTELLIGENCE (AI)? If approved, it would be the first medication to treat IBD by blocking prolyl hydroxylase domain (PHD), a protein that regulates the body's gut barrier protection genes, according to Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

Inflammatory bowel disease (IBD) is a chronic disease with unknown pathophysiological mechanisms. There is evidence of the role of microorganims in this disease development. Thanks to the open access to multiple omics data, it is possible to develop predictive models that are able to prognosticate the course and development of the disease. The interpretability of these models, and the study of the variables used, allows the identification of biological aspects of great importance in the development of the disease. In this work we generated a metagenomic signature with predictive capacity to identify IBD from fecal samples.

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is an idiopathic condition related to a dysregulated immune response to commensal intestinal microflora in a genetically susceptible host. As a global disease, the morbidity of IBD reached a rate of 84.3 per 100,000 persons and reflected a continued gradual upward trajectory. The medical cost of IBD is also notably extremely high. For example, in Europe, it has €3,500 in CD and €2,000 in UC per patient per year, respectively. In addition, taking into account the work productivity loss and the reduced quality of life, the indirect costs are incalculable. In modern times, the diagnosis of IBD is still a subjective judgment based on laboratory tests and medical images. Its early diagnosis and intervention is therefore a challenging goal and also the key to control its progression. Artificial intelligence (AI)-assisted diagnosis and prognosis prediction has proven effective in many fields including gastroenterology. In this study, support vector machines were utilized to distinguish the significant features in IBD. As a result, the reliability of IBD diagnosis due to its impressive performance in classifying and addressing region problems was improved. Convolutional neural networks are advanced image processing algorithms that are currently in existence. Digestive endoscopic images can therefore be better understood by automatically detecting and classifying lesions. This study a...

Precision medicine holds great promise to improve the landscape of IBD course of care for an individual patient, providing the most beneficial therapy while minimising the risk. The ultimate goals of precision medicine include stratifying patients based on disease subtypes and severity, disease progression and treatment response using personal and clinical data coupled with molecular profiling data of patients.1 2 IBD, with its two main subtypes, Crohn's disease (CD) and UC, is a complex inflammatory disease with a wide range of contributing factors including host genetics, immune system, environmental exposures and the gut microbiome.3–5 The inherent complexity of the disease introduces a large number of confounding factors, which stand in the way of accurate diagnosis and precision medicine.6 The term'big data' is generally referred to as large volume of rapidly produced data from variable sources, known as the three'V's (volume, velocity and variety).7 Over the past decades, the production and availability of data that could inform healthcare has increased remarkably mainly due to technological advancements and falling costs of data generation.

Tech giants Apple (AAPL), Alphabet (GOOGL), Facebook (FB), and Microsoft (MSFT) have raced to apply artificial intelligence to their businesses, and the oil industry is starting to seize on AI's benefits too. The reason interest is surging now is because artificial intelligence is "actually doable," he said in an interview with IBD at CERAWeek, explaining that advancements in cloud computing and infrastructure have made AI more affordable and accessible. "The industrial world is waking up to best practices," he said. "They are all waking up to it." Several heavyweights in the energy industry are already investors in his company, including General Electric (GE), Chevron (CVX), Royal Dutch Shell (RDSA) and Saudi Aramco.

Graphics chip maker Nvidia (NVDA) is well-positioned to fight off emerging competitors in the market for chips for artificial-intelligence applications, a Wall Street analyst said Tuesday. These rivals include application-specific integrated circuits (ASICs) or semi-custom chip systems such as Alphabet (GOOGL)-owned Google's tensor processing units, Intel's (INTC) Nervana, and upcoming systems from privately held Graphcore and Cerebras Systems, Mosesmann said. "It is possible for ASICs over time to be successful in the deep-learning world," Mosesmann said. "However, we are of the opinion that at this stage in a multidecade product cycle it is just too early to'fix' the hardware, given that there is a plethora of deep-learning frameworks (Tensorflow, Caffee, MXNet, CNTK, etc.), that may take years to settle on which open-sourced varietals will win." Customers will gravitate to Nvidia's GPUs for deep learning in part because of the company's compute-platform and programming model, called CUDA, he said.

Salesforce.com (CRM) stock hit a all-time high on Thursday as Barclay's raised its price target on the enterprise software maker with a bullish view of its artificial intelligence tools. Barclays hiked its price target to 127 from 117. Salesforce.com gained 1.6% to close at 111.77 on the stock market today, hitting a new high. "The combination of its AI capabilities (through Einstein) and the largest CRM (customer relationship management) database in the world (a key input factor for any AI model), will enable salesforce to offer the most powerful system in the space, which enables better pricing and customer retention," said Raimo Lenschow, a Barclays analyst in a report. Shares in Salesforce.com have jumped nearly 10% in 2018 and are up 47% from a year ago.

As its stock hit a record high Friday, Microsoft's (MSFT) price target was raised on the view that its products and initiatives around artificial intelligence are undervalued. X KeyBanc Capital Markets analyst Brent Bracelin raised his price target on Microsoft to 106 from 94 and maintained a rating of overweight. "After meeting with senior leaders at Microsoft who are spearheading new AI products and initiatives, we came away impressed with Microsoft's AI product scope, ambitions to differentiate, and the three-year potential to capitalize on this wide-open market opportunity," Bracelin wrote in a research note to clients. Microsoft shares climbed 1.7% near 89.60 on the stock market today, setting a new high. Bracelin said he met with senior leaders at Microsoft last month and came away "very impressed by Microsoft's AI platform and the traction with embedding and implementing AI services in the enterprise."